TATVA · Tatva Chintan Pharma Chem Ltd · Chemical Manufacturing
TATVA · Tatva Chintan Pharma Chem Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
21.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹167 Cr
Revenue YoY
PAT YoY
+140.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4.7
P/S (TTM)
6.8
Sector P/E
20.6
Dividend yield
+0.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| TATVA (this stock) | 54.4 | 4.7 | +9.2% | +6.6% | 0.15 | +0.1% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Solar Industries India | 99.6 | 26.6 | +17.6% | +31.4% | 13.68 | +0.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
Promoter
stable
FII
rising 1q
MF
2.79% (-0.08pp)
falling 3q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation for Tatva Chintan Pharma Chem Limited (TATVA) for Q2 FY27 highlights a 76% year-over-year revenue growth, reaching ₹2,173 million, with a 19% EBITDA margin. The company achieved its highest-ever quarterly turnover, driven by growth in its Structured Directing Agents (SDA) and Phase Transfer Catalysts (PTC) segments. However, EBITDA remained stable due to temporary factors like solvent price hikes (60%-100% increase) and global freight costs (over 100% increase in US and Europe), which are expected to normalize by Q3 FY27. The presentation notes strong performance in SDA, supported by the implementation of EURO 7 emission standards, and progress in energy storage initiatives. The Pharma, Agro, and Specialty Chemicals business is gaining momentum, with new products contributing to revenue. The company emphasizes sustainable practices, including green chemistry and zero liquid effluent discharge facilities. Management prioritizes maintaining revenue growth and converting it into sustainable profits, with confidence in long-term opportunities. The consolidated financials show a 60% year-over-year revenue increase for H1 FY27, with PAT margin at 9.7% and a debt-to-equity ratio of 4.30. The company also outlines its global presence, with subsidiaries in the US and Netherlands, and a diversified product portfolio across specialty chemicals.
The tone_label is Positive as the document emphasizes record revenue, growth in key segments, and confidence in long-term opportunities, despite temporary challenges.
Sourced from an exchange-filed presentation, dated 19 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tatva Chintan Pharma Chem Limited held its Q1 FY27 earnings conference call on July 17, 2026, where management reported significant financial growth. The company achieved operating revenue of INR 1,671 million, marking a 43% year-on-year increase and a 25% sequential rise. EBITDA reached INR 323 million, reflecting an 86% year-on-year growth. Segment-wise, Phase Transfer Catalysts generated INR 428 million in revenue, while Electrolyte Salts saw a decline of 52% sequentially but a 76% year-on-year increase. Management highlighted the positive developments across multiple business segments and announced plans for a new greenfield manufacturing facility with an investment of approximately INR 200 crores. The management expressed confidence in the company's growth trajectory, citing increased customer demand and the successful qualification of products in the semiconductor sector. The call concluded with management thanking stakeholders for their support and emphasizing the company's commitment to innovation and growth.
Management emphasized strong financial performance and growth opportunities across various segments.
Sourced from an exchange-filed transcript, dated 21 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tatva Chintan Pharma Chem Limited's investor presentation for the quarter ended June 30, 2026, highlighted significant financial performance improvements. The company reported a 43% year-over-year increase in revenue from operations, reaching ₹1,671 million, and an 86% increase in EBITDA, amounting to ₹323 million. Profit After Tax (PAT) also saw a substantial rise of 140%, totaling ₹160 million. The presentation detailed the company's diverse product categories, including Phase Transfer Catalysts and Structure Directing Agents, which contributed to its revenue growth. Management emphasized the company's commitment to sustainable practices and advanced technology, with a focus on green chemistry processes. The document outlined Tatva's expansive international presence, serving over 25 countries, and its strategic positioning within the specialty chemicals market. The company aims to leverage its R&D capabilities and established market relationships to drive future growth.
Management emphasized strong financial growth and sustainable practices.
Sourced from an exchange-filed presentation, dated 17 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tatva Chintan Pharma Chem Limited's investor presentation for the quarter and financial year ended March 31, 2026, reported a revenue from operations of ₹5,059 million, reflecting a year-on-year increase of 32%. The presentation highlighted a significant rise in EBITDA, which reached ₹932 million, up 172% from the previous year. Profit After Tax (PAT) also saw a substantial increase of 636%, amounting to ₹421 million. The company emphasized its diverse product portfolio, with key categories including Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts (ESS), and Pharmaceutical and Agrochemical Intermediates (PASC). Management noted the company's commitment to sustainable practices and advanced technology, with a focus on green chemistry processes. The presentation outlined Tatva's expansive international presence, serving over 25 countries, and its strategic positioning within the specialty chemicals market.
Management emphasized strong financial performance and growth in product categories.
Sourced from an exchange-filed presentation, dated 16 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedTatva Chintan Pharma Chem Limited's FY2025-26 annual report highlights its strategic focus on innovation, sustainability, and global market expansion. The company emphasizes its leadership in specialty chemicals, particularly in Structure Directing Agents (SDA) and Phase Transfer Catalysts (PTC), while expanding its environmental stewardship initiatives. The report outlines continued investment in R&D, manufacturing capacity, and international presence through subsidiaries in the USA and Europe. The company also underscores its commitment to corporate governance and social responsibility.
- Leadership in specialty chemicals with a focus on Structure Directing Agents (SDA) and Phase Transfer Catalysts (PTC)
- Commitment to sustainability and environmental stewardship through green chemistry initiatives
- Expansion of manufacturing capacity and global presence via subsidiaries in the USA and Europe
- Emphasis on R&D and innovation to maintain competitive advantage
- Strong corporate governance practices and adherence to regulatory standards
Key takeaway: Tatva Chintan Pharma Chem Limited is positioning itself as a global leader in specialty chemicals through innovation, sustainability, and strategic expansion, while maintaining a strong focus on corporate governance and environmental responsibility.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
The company received a show cause notice dated 22 September 2022 under section 274 read with section 270A of the Income Tax Act, 1961 for disallowances of ₹1.00 million (AY 2020–21) and an order dated 24 March 2025 under section 147 read with section 144B for disallowance of ₹10.20 million for AY 2020–21.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The Holding Company received a show-cause-cum-demand notice from DGGI alleging erroneous IGST refund of ₹11.38 million for FY 2017–18 and 2018–19, demanding tax recovery of ₹11.38 million along with a penalty.
Earlier (1-3 years ago)
The company has received show cause-cum-demand notices from DGGI (GST Intelligence) for erroneous IGST refunds totaling ₹11.38 million (FY 2017–18 and 2018–19), including interest and penalties, and another notice for ₹0.56 million plus interest, with the company contesting both and expecting favorable outcomes.
The company has contingent liabilities related to indirect tax matters and direct tax claims, with pending proceedings where cash outflows cannot be estimated until judgments or decisions are received.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The Company has entered into transactions with related parties in compliance with the provisions of sections 177 and 188 of the Act. The details of such related party transactions have been disclosed in the standalone financial statements.
Earlier (1-3 years ago)
The company has details of related party transactions in its CSR activities for the years ended 31 March 2025 and 31 March 2024.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has an outstanding dispute-related unpaid Goods and Service Tax amounting to 2017-18 million under the Integrated Goods and Service Tax Act, 2017, with the Additional Commissioner GST and C.
Earlier (1-3 years ago)
TATVA CHINTAN PHARMA CHEM LIMITED has outstanding statutory dues of Goods and Service Tax (2017-18) pending before the Additional Commissioner GST and Central Excise (Appeals), and Goods and Service Tax (2017-18 and 2018-19) pending before the Deputy Director General of GST Intelligence (DGGI), along with Income Tax (2019-20) pending before the Commissioner of Income Tax (Appeals).